FOXP3 and colitis: Indeed, treatment with Vivomixx® alleviated the development of “clinical” signs and symptoms of colitis, reduced inflammation (as measured by assessing the macroscopic and histopathological scores) and induced a regulatory immune response, as highlighted by the increased expression of signature cytokines such IL-10 along with Foxp3, a marker of Treg polarization.